Form 4: Palvella Therapeutics COO Awarded Stock Options

Kathleen Goin, COO of Palvella Therapeutics, was granted incentive and non-qualified stock options on February 5, 2025.

Summary

• On February 5, 2025, Kathleen Goin, the Chief Operating Officer of Palvella Therapeutics, received stock options.
• These options include both incentive stock options (5,373 shares) and non-qualified stock options (123,559 shares).
• The exercise price for both types of options is $14.76 per share.
• The options vest in equal monthly installments over 48 months and expire on February 5, 2035.
• Following the transaction, Ms. Goin directly owns 5,373 incentive stock options and 123,559 non-qualified stock options.

Sentiment

Score: 7

Explanation: The document indicates a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management and shareholder interests.

Positives

• The grant of stock options to the COO aligns her interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the COO.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and align management interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
• The size of the grant and the vesting schedule are typical for a COO position in a company of Palvella Therapeutics' size and stage of development.
• Comparable companies often use similar equity-based compensation to attract and retain key personnel.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the COO to improve company performance.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates